Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, gives an overview of the Phase II MiST trial (NCT03654833) investigating stratified therapy for the treatment of mesothelioma. Prof. Fennell outlines how mutations in BAP1 and BRCA1 can be used to predict response to PARP inhibitors such as rucaparib. The study will also explore the impact of mutations of the gene CDKN2a on CDK4/6 inhibitor therapy with abemaciclib, and the role of immunotherapy with pembrolizumab plus bemcentinib, atezolizumab plus bevacizumab or dostarlimab and niraparib in the relapsed setting is being investigated. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

свернуть